Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Sanctura Articles

Indevus makes $105M placing

1 September 2008

Allergan gets Canadian right to Sanctura

2 June 2008

Indevus' loss doubles on charges in fiscal 2007

10 December 2007

Allergan buys Esprit Pharma for $370M in cash

27 September 2007

Indevus gets $49.9M milestone from Esprit

20 August 2007

Indevus' Sanctura XR approved by US FDA

13 August 2007

Indevus licenses European Sanctura XR rights to Madaus

13 November 2006

Strong Ph III data for Indevus' Sanctura XR

17 July 2006

Indevus closes Sanctura transaction with Esprit

11 July 2005

Pliva's overactive bladder drug Sanctura launched in USA

13 September 2004

Indevus' Sanctura cleared by FDA

7 June 2004

Indevus and Pliva to co-promote Sanctura

12 April 2004

Indevus files for OAB drug trospium in USA

5 May 2003

Interneuron revenues up on Sarafem royalty

25 February 2002

Interneuron begins Ph III trospium trial

7 September 2001

Interneuron crashes again as citicoline fails in stroke

13 January 2000

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS